Do analysts prefer PRTC or VIR?

Vir Biotechnology has a consensus price target of $20.88, indicating a potential upside of 119.48%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vir Biotechnology 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89

Which has preferable earnings and valuation, PRTC or VIR?

PureTech Health has higher earnings, but lower revenue than Vir Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Vir Biotechnology $68.56M 23.40 -$437.99M -$3.13 N/A

Does the media prefer PRTC or VIR?

In the previous week, Vir Biotechnology had 1 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Vir Biotechnology and 2 mentions for PureTech Health. Vir Biotechnology's average media sentiment score of 1.81 beat PureTech Health's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer HROW or PRTC?

Harrow presently has a consensus target price of $69.43, suggesting a potential upside of 66.88%. Given Harrow's stronger consensus rating and higher possible upside, equities research analysts clearly believe Harrow is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, HROW or PRTC?

Harrow has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 5.70 -$5.14M -$0.41 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media refer more to HROW or PRTC?

In the previous week, Harrow and Harrow both had 2 articles in the media. Harrow's average media sentiment score of 0.94 beat PureTech Health's score of 0.00 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend IMCR or PRTC?

Immunocore currently has a consensus price target of $56.71, indicating a potential upside of 72.60%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts plainly believe Immunocore is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunocore 1 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.40 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, IMCR or PRTC?

Immunocore has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunocore $400.02M 4.18 -$35.51M -$0.55 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media favor IMCR or PRTC?

In the previous week, Immunocore had 4 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Immunocore and 2 mentions for PureTech Health. Immunocore's average media sentiment score of 0.18 beat PureTech Health's score of 0.00 indicating that Immunocore is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunocore 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend AVBP or PRTC?

ArriVent BioPharma currently has a consensus price target of $44.83, suggesting a potential upside of 36.81%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe ArriVent BioPharma is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ArriVent BioPharma 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, AVBP or PRTC?

PureTech Health has higher revenue and earnings than ArriVent BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is AVBP or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% PureTech Health N/A N/A N/A

Does the media prefer AVBP or PRTC?

In the previous week, ArriVent BioPharma had 2 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for ArriVent BioPharma and 2 mentions for PureTech Health. ArriVent BioPharma's average media sentiment score of 0.62 beat PureTech Health's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PRTC or MRVI?

Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 14.00%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Maravai LifeSciences 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has better valuation & earnings, PRTC or MRVI?

PureTech Health has higher earnings, but lower revenue than Maravai LifeSciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PureTech Health $4.66M 91.01 -$109.74M N/A N/A Maravai LifeSciences $185.74M 8.89 -$130.77M -$0.71 N/A

Does the media refer more to PRTC or MRVI?

In the previous week, PureTech Health and PureTech Health both had 2 articles in the media. Maravai LifeSciences' average media sentiment score of 1.87 beat PureTech Health's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

PureTech Health (PRTC) Competitors

$17.42 0.00 (0.00%)

As of 07/10/2026

Compare

PRTC vs. VIR, HROW, IMCR, AVBP, and MRVI

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Vir Biotechnology (VIR), Harrow (HROW), Immunocore (IMCR), ArriVent BioPharma (AVBP), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does PureTech Health compare to Vir Biotechnology?

PureTech Health (NASDAQ:PRTC) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Vir Biotechnology had 1 more articles in the media than PureTech Health. MarketBeat recorded 3 mentions for Vir Biotechnology and 2 mentions for PureTech Health. Vir Biotechnology's average media sentiment score of 1.81 beat PureTech Health's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PureTech Health has higher earnings, but lower revenue than Vir Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Vir Biotechnology	$68.56M	23.40	-$437.99M	-$3.13	N/A

PureTech Health has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. PureTech Health's return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Vir Biotechnology	-638.88%	-53.31%	-41.76%

Vir Biotechnology has a consensus price target of $20.88, indicating a potential upside of 119.48%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market.

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Vir Biotechnology beats PureTech Health on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Harrow?

Harrow (NASDAQ:HROW) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Harrow presently has a consensus target price of $69.43, suggesting a potential upside of 66.88%. Given Harrow's stronger consensus rating and higher possible upside, equities research analysts clearly believe Harrow is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PureTech Health has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
PureTech Health	N/A	N/A	N/A

72.8% of Harrow shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Harrow has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.70	-$5.14M	-$0.41	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

In the previous week, Harrow and Harrow both had 2 articles in the media. Harrow's average media sentiment score of 0.94 beat PureTech Health's score of 0.00 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harrow has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Summary

Harrow beats PureTech Health on 10 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Immunocore?

Immunocore (NASDAQ:IMCR) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

Immunocore has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$400.02M	4.18	-$35.51M	-$0.55	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

PureTech Health has a net margin of 0.00% compared to Immunocore's net margin of -6.68%. PureTech Health's return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-6.68%	-7.07%	-2.55%
PureTech Health	N/A	N/A	N/A

84.5% of Immunocore shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 10.1% of Immunocore shares are held by company insiders. Comparatively, 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Immunocore had 4 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Immunocore and 2 mentions for PureTech Health. Immunocore's average media sentiment score of 0.18 beat PureTech Health's score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunocore has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

Immunocore currently has a consensus price target of $56.71, indicating a potential upside of 72.60%. Given Immunocore's stronger consensus rating and higher possible upside, research analysts plainly believe Immunocore is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Immunocore beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

ArriVent BioPharma has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, ArriVent BioPharma had 2 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for ArriVent BioPharma and 2 mentions for PureTech Health. ArriVent BioPharma's average media sentiment score of 0.62 beat PureTech Health's score of 0.00 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ArriVent BioPharma currently has a consensus price target of $44.83, suggesting a potential upside of 36.81%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe ArriVent BioPharma is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PureTech Health's return on equity of 0.00% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
PureTech Health	N/A	N/A	N/A

PureTech Health has higher revenue and earnings than ArriVent BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Summary

ArriVent BioPharma beats PureTech Health on 9 of the 13 factors compared between the two stocks.

How does PureTech Health compare to Maravai LifeSciences?

PureTech Health (NASDAQ:PRTC) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

PureTech Health has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -51.07%. PureTech Health's return on equity of 0.00% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

PureTech Health has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

In the previous week, PureTech Health and PureTech Health both had 2 articles in the media. Maravai LifeSciences' average media sentiment score of 1.87 beat PureTech Health's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Maravai LifeSciences has a consensus price target of $5.50, indicating a potential downside of 14.00%. Given Maravai LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

PureTech Health has higher earnings, but lower revenue than Maravai LifeSciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A
Maravai LifeSciences	$185.74M	8.89	-$130.77M	-$0.71	N/A

Summary

PureTech Health beats Maravai LifeSciences on 7 of the 13 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$424.04M	$3.64B	$6.76B	$12.50B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	N/A	20.96	26.93	24.41
Price / Sales	91.01	313.81	586.18	117.36
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	1.38	8.50	10.94	6.33
Net Income	-$109.74M	$23.83M	$3.58B	$330.66M
7 Day Performance	N/A	-3.12%	-2.10%	-0.66%
1 Month Performance	N/A	6.61%	3.21%	-0.14%
1 Year Performance	-0.77%	48.58%	26.34%	20.16%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	0.0335 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100	News Coverage
VIR Vir Biotechnology	2.6635 of 5 stars	$10.25 +2.3%	$20.88 +103.7%	+72.0%	$1.69B	$68.56M	N/A	580	News Coverage Positive News
HROW Harrow	4.2903 of 5 stars	$46.15 +2.7%	$69.43 +50.4%	+19.7%	$1.67B	$272.30M	N/A	180
IMCR Immunocore	3.3557 of 5 stars	$33.40 +4.6%	$56.71 +69.8%	-7.2%	$1.62B	$400.02M	N/A	320	Analyst Downgrade High Trading Volume
AVBP ArriVent BioPharma	2.7281 of 5 stars	$34.18 -0.9%	$43.14 +26.2%	+55.5%	$1.61B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRTC) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. VIR, HROW, IMCR, AVBP, and MRVI

How does PureTech Health compare to Vir Biotechnology?

Summary

How does PureTech Health compare to Harrow?

Summary

How does PureTech Health compare to Immunocore?

Summary

How does PureTech Health compare to ArriVent BioPharma?

Summary

How does PureTech Health compare to Maravai LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. VIR, HROW, IMCR, AVBP, and MRVI

How does PureTech Health compare to Vir Biotechnology?

Does the media prefer PRTC or VIR?

Which has preferable earnings and valuation, PRTC or VIR?

Is PRTC or VIR more profitable?

Do analysts prefer PRTC or VIR?

Which has more risk & volatility, PRTC or VIR?

Do institutionals and insiders believe in PRTC or VIR?

Summary

How does PureTech Health compare to Harrow?

Do analysts prefer HROW or PRTC?

Is HROW or PRTC more profitable?

Do institutionals & insiders hold more shares of HROW or PRTC?

Which has preferable earnings and valuation, HROW or PRTC?

Does the media refer more to HROW or PRTC?

Which has more risk and volatility, HROW or PRTC?

Summary

How does PureTech Health compare to Immunocore?

Which has better valuation & earnings, IMCR or PRTC?

Is IMCR or PRTC more profitable?

Do institutionals & insiders believe in IMCR or PRTC?

Does the media favor IMCR or PRTC?

Which has more risk & volatility, IMCR or PRTC?

Do analysts recommend IMCR or PRTC?

Summary

How does PureTech Health compare to ArriVent BioPharma?

Which has more risk and volatility, AVBP or PRTC?

Does the media prefer AVBP or PRTC?

Do analysts recommend AVBP or PRTC?

Do insiders and institutionals have more ownership in AVBP or PRTC?

Is AVBP or PRTC more profitable?

Which has better earnings & valuation, AVBP or PRTC?

Summary

How does PureTech Health compare to Maravai LifeSciences?

Is PRTC or MRVI more profitable?

Which has more volatility & risk, PRTC or MRVI?

Does the media refer more to PRTC or MRVI?

Do insiders and institutionals believe in PRTC or MRVI?

Do analysts recommend PRTC or MRVI?

Which has better valuation & earnings, PRTC or MRVI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools